Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1981;20(6):465-71.
doi: 10.1007/BF00542101.

Single-dose pharmacokinetics of metoclopramide

Comparative Study

Single-dose pharmacokinetics of metoclopramide

L M Ross-Lee et al. Eur J Clin Pharmacol. 1981.

Abstract

The time courses of plasma metoclopramide concentrations were followed in six subjects after oral and intravenous single dose administration. Plasma concentration-time data following i. v. administration in each subject were found to fit a two compartment model with a mean terminal half-life of 4.55 h +/- 0.80 h and a mean distribution half-time of 0.35 h +/- 0.09 h. Volumes of distribution were high (3.43 +/- 1.181 . kg-1), and clearances (0.53 +/- 0.191 . kg-1 h-1) approached liver plasma flow. This suggests that metoclopramide occurs at higher concentrations in tissues than in plasma, and that its clearance is probably limited by liver blood flow rather than liver metabolic capacity. The postabsorption decline in metoclopramide plasma levels after oral administration was also biexponential in each subject. The terminal half-life was 5.17 h +/- 0.98 h. Mean volume of distribution and mean clearance were similar to intravenous values (after adjustment for bioavailability). Oral absorption was rapid with peak plasma concentrations being reached at a mean time of 0.93 h. A mean bioavailability of 0.77 was calculated for the six subjects, and it was postulated that this incomplete availability is due to a first-pass effect. The inter-individual variation in the degree of "first-pass' was considerable (0.47--1.14).

PubMed Disclaimer

References

    1. J Pharm Sci. 1975 Oct;64(10):1734-5 - PubMed
    1. J Pharm Pharmacol. 1975 Dec;27 Suppl?-2:42P - PubMed
    1. Br J Clin Pharmacol. 1979 Nov;8(5):469-74 - PubMed
    1. J Pharm Sci. 1978 Aug;67(8):1073-7 - PubMed
    1. Chem Pharm Bull (Tokyo). 1970 Aug;18(8):1663-9 - PubMed

Publication types

LinkOut - more resources